These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27129776)

  • 41. Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in colo 205 human colon cancer cells in vitro and in vivo.
    Lai KC; Kuo CL; Ho HC; Yang JS; Ma CY; Lu HF; Huang HY; Chueh FS; Yu CC; Chung JG
    Phytomedicine; 2012 May; 19(7):625-30. PubMed ID: 22397993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diallyl sulfide, diallyl disulfide, and diallyl trisulfide inhibit migration and invasion in human colon cancer colo 205 cells through the inhibition of matrix metalloproteinase-2, -7, and -9 expressions.
    Lai KC; Hsu SC; Kuo CL; Yang JS; Ma CY; Lu HF; Tang NY; Hsia TC; Ho HC; Chung JG
    Environ Toxicol; 2013 Sep; 28(9):479-88. PubMed ID: 21695758
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
    Li M; Pan M; You C; Zhao F; Wu D; Guo M; Xu H; Shi F; Zheng D; Dou J
    Breast Cancer Res; 2020 Mar; 22(1):26. PubMed ID: 32143670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-κB Activation.
    Pan Y; Lin S; Xing R; Zhu M; Lin B; Cui J; Li W; Gao J; Shen L; Zhao Y; Guo M; Wang JM; Huang J; Lu Y
    Antioxid Redox Signal; 2016 May; 24(15):839-54. PubMed ID: 26801633
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells.
    Zhang Q; Li XT; Chen Y; Chen JQ; Zhu JY; Meng Y; Wang XQ; Li Y; Geng SS; Xie CF; Wu JS; Zhong CY; Han HY
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):969-977. PubMed ID: 29594332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diallyl trisulfide inhibits estrogen receptor-α activity in human breast cancer cells.
    Hahm ER; Singh SV
    Breast Cancer Res Treat; 2014 Feb; 144(1):47-57. PubMed ID: 24487688
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Activation of a novel ataxia-telangiectasia mutated and Rad3 related/checkpoint kinase 1-dependent prometaphase checkpoint in cancer cells by diallyl trisulfide, a promising cancer chemopreventive constituent of processed garlic.
    Herman-Antosiewicz A; Stan SD; Hahm ER; Xiao D; Singh SV
    Mol Cancer Ther; 2007 Apr; 6(4):1249-61. PubMed ID: 17406033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The FoxQ1 transcription factor is a novel regulator of electron transport chain complex I subunits in human breast cancer cells.
    Kim SH; Singh SV
    Mol Carcinog; 2022 Mar; 61(3):372-381. PubMed ID: 34939230
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses.
    Azzam DJ; Zhao D; Sun J; Minn AJ; Ranganathan P; Drews-Elger K; Han X; Picon-Ruiz M; Gilbert CA; Wander SA; Capobianco AJ; El-Ashry D; Slingerland JM
    EMBO Mol Med; 2013 Oct; 5(10):1502-22. PubMed ID: 23982961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.
    Lai KC; Hsu SC; Yang JS; Yu CC; Lein JC; Chung JG
    J Cell Mol Med; 2015 Feb; 19(2):474-84. PubMed ID: 25403643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo.
    Stivarou T; Stellas D; Vartzi G; Thomaidou D; Patsavoudi E
    Cancer Biol Ther; 2016 Aug; 17(8):799-812. PubMed ID: 27259689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
    Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
    Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
    Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
    Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insight into drug sensitizing effect of diallyl disulfide and diallyl trisulfide from Allium sativum L. on paclitaxel-resistant triple-negative breast cancer cells.
    Marni R; Kundrapu DB; Chakraborti A; Malla R
    J Ethnopharmacol; 2022 Oct; 296():115452. PubMed ID: 35690339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diallyl trisulfide suppresses tumor growth through the attenuation of Nrf2/Akt and activation of p38/JNK and potentiates cisplatin efficacy in gastric cancer treatment.
    Jiang XY; Zhu XS; Xu HY; Zhao ZX; Li SY; Li SZ; Cai JH; Cao JM
    Acta Pharmacol Sin; 2017 Jul; 38(7):1048-1058. PubMed ID: 28344324
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of CD44+ALDH1+Ki-67- Cells in Non-malignant and Neoplastic Lesions of the Breast.
    DA Cruz Paula A; Marques O; Sampaio R; Rosa A; Garcia J; Rêma A; DE Fátima Faria M; Silva P; Vizcaíno R; Lopes C
    Anticancer Res; 2016 Sep; 36(9):4629-38. PubMed ID: 27630305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.